Risedronate sodium
( DrugBank: Risedronate sodium / KEGG DRUG: Risedronate sodium, Risedronic acid, Risedronate sodium monohydrate )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 50 | Dermatomyositis | 1 |
| 107 | Juvenile idiopathic arthritis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 1 |
| 274 | Osteogenesis Imperfecta | 12 |
50. Dermatomyositis
Clinical trials : 231 / Drugs : 216 - (DrugBank : 55) / Drug target genes : 59 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
107. Juvenile idiopathic arthritis
Clinical trials : 477 / Drugs : 232 - (DrugBank : 53) / Drug target genes : 66 - Drug target pathways : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
113. Muscular dystrophy
Clinical trials : 766 / Drugs : 477 - (DrugBank : 119) / Drug target genes : 80 - Drug target pathways : 178
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
274. Osteogenesis Imperfecta
Clinical trials : 102 / Drugs : 82 - (DrugBank : 22) / Drug target genes : 15 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|